Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01563978 · ClinicalTrials.gov registry record · Phase 2
Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis
A Phase 2 study of Rheumatoid Arthritis, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 266
- Enrollment target
- 20
- Study locations
NCT01563978: Completed Phase 2 study of Rheumatoid Arthritis, sponsored by AstraZeneca.
NCT01563978 is a Phase 2 study of Rheumatoid Arthritis that has completed, run by AstraZeneca. The registered enrollment target is 266 participants, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01563978, a Phase 2 study of Rheumatoid Arthritis, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 266 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the effect of fostamatinib compared to placebo on ambulatory blood pressure in patients with active rheumatoid arthritis who are taking a disease-modifying anti-rheumatic drug (DMARD). The study will last for 57 days.
Primary Outcome
ANCOVA=analysis of covariance, BID=twice daily, FAS=full analysis set, IP=investigational product, SBP=systolic blood pressure.
Conditions Studied
Interventions
- DRUG placebo
- DRUG fostamatinib
Study Locations (20)
Florida
- Research Site - Boca Raton
- Research Site - Brandon
- Research Site - Orlando
- Research Site - Tampa
- Research Site - Venice
Maryland
- Research Site - Cumberland
- Research Site - Frederick
- Research Site - Hagerstown
California
- Research Site - Huntington Beach
- Research Site - Santa Maria
Missouri
- Research Site - Florissant
- Research Site - Richmond Heights
Alabama
- Research Site - Huntsville
Connecticut
- Research Site - Trumbull
Georgia
- Research Site - Decatur
Indiana
- Research Site - South Bend
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 266 participants |
| Start Date | 2012-04 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
What the finished NCT01563978 record still lists
NCT01563978 is an interventional study that assigns participants to a tested intervention. The registered 266 participants enrollment target is mid-sized for trials with a published cap, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01563978 names 20 study sites across 12 states, led by Florida, Maryland, California.
Frequently Asked Questions
What is clinical trial NCT01563978 about?
NCT01563978 is a clinical study titled "Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis". The purpose of this study is to evaluate the effect of fostamatinib compared to placebo on ambulatory blood pressure in patients with active rheumatoid arthritis who are taking a disease-modifying anti-rheumatic drug (DMARD). The study will last for 57 days.
What is the current status of trial NCT01563978?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 266 participants. The study started on 2012-04. Estimated completion is 2013-01.
What conditions does trial NCT01563978 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT01563978?
The interventions under investigation include: placebo (DRUG), fostamatinib (DRUG).
Who is sponsoring clinical trial NCT01563978?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01563978 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01563978's enrollment target sits among peer trials
266 68th of 197 higher than 129 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of SPY072 in Rheumatic Disease
RECRUITING · Phase 2
-
Dynamic Treatment Regiments for Glucocorticoid Tapering
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
RECRUITING · Phase 2
-
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05098652 · 266 participants · NA
Coaching Dementia Caregivers to Master Care-Resistant Behavior
- NCT06088277 · 266 participants · NA
Texting to Reduce Human Immunodeficiency Virus (HIV) Risk
- NCT06261814 · 266 participants · Phase 2
Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors
- NCT06312124 · 266 participants · NA
A Study of Opportunistic Salpingectomy to Prevent Ovarian Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia